PLRX — Pliant Therapeutics Share News
0.000.00%
Last trade - 00:00- $50.52m
- -$107.59m
Brief: Pliant Therapeutics Q3 Net Income USD -57.763 Million Vs. IBES Estimate USD -59.3 Million
Brief: Aligos Therapeutics Strengthens Senior Leadership Team With The Appointment Of Hardean Achneck, MD As Chief Medical Officer
Pliant Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Pliant Therapeutics Q2 Net Income USD -55.854 Million Vs. IBES Estimate USD -50.9 Million
Pliant Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview
Brief: Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial
Brief: Pliant Therapeutics Inc - Increased Authorized Size Of Board From Ten To Eleven Members
Pliant Therapeutics rises as lung disease drug succeeds in mid-stage study
Brief: Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pliant Therapeutics Q1 Net Income USD -46.955 Million Vs. IBES Estimate USD -46.3 Million
Pliant Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Pliant Therapeutics Amendment To May 2022 $100 Million Loan Facility With Oxford Finance, Upsizing Facility To $150 Million Of Available Non-Dilutive Capital
Brief: Pliant Therapeutics Provides Corporate Update And Reports Fourth Quarter 2023 Financial Results
Brief: Pliant Therapeutics Q4 Net Income USD -41.109 Million
U.S. RESEARCH ROUNDUP-Air Products and Chemicals , Hubspot and McDonald's
Brief: Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data Phase 2A Of Bexotegrast
Brief: Pliant Therapeutics Q3 Net Income USD -41.487 Million
Pliant Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview